Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Nexavar

02 1NexavarTM

PharmaCompass

01

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 773

2019 Revenue in Millions : 854

Growth (%) : -9

Company Banner

02

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 479

2020 Revenue in Millions : 773

Growth (%) : -32

Company Banner

03

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 280

2021 Revenue in Millions : 479

Growth (%) : -41

Company Banner

04

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 850

2014 Revenue in Millions : 981

Growth (%) : 15%

Company Banner

05

Brand Name : NexavarTM

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2014 Revenue in Millions : 0.30%

2013 Revenue in Millions :

Growth (%) :

Company Banner

06

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 1,034

2016 Revenue in Millions : 1,079

Growth (%) : -4

Company Banner

07

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 922

2015 Revenue in Millions : 946

Growth (%) : -2

Company Banner

08

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 805

2017 Revenue in Millions : 942

Growth (%) : -15%

Company Banner

09

Brand Name : Nexavar

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Sorafenib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 770

2018 Revenue in Millions : 776

Growth (%) : -1

Company Banner